Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells

Journal of Immunology

Volumn 177, Issue 9, 2006, Pages 5946-5955

  Enomoto, Yutaka ^a   Bharti, Ajit ^a   Khaleque, Ad Abdul ^b   Song, Baizheng ^a   Liu, Chunlei ^a   Apostolopoulos, Vasso ^c   Xing, Pei Xiang ^c   Calderwood, Stuart K ^b   Gong, Jianlin ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 PEPTIDE COMPLEX; HEAT SHOCK PROTEIN 90; PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL FUSION; CELL MATURATION; CELL STIMULATION; COMPLEX FORMATION; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; GENE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPRECIPITATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MOUSE; MYD88 GENE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 33750359212     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.9.5946     Document Type: Article

References (55)

1. Lindquist, S., and E. A. Craig. 1988. The heat-shock proteins. Annu. Rev. Genet. 22: 631-677.
2. Georgopoulos, C., and W. J. Welch. 1993. Role of the major heat shock proteins as molecular chaperones. Annu. Rev. Cell Biol. 9: 601-634.
3. Udono, H., and P. K. Srivastava. 1993. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178: 1391-1396.
4. Arnold, D., S. Faath, H. Rammensee, and H. Schild. 1995. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182: 885-889
5. Heikema, A., E. Agsteribbe, J. Wilschut, and A. Huckriede. 1997. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol. Lett. 57: 69-74.
6. Ciupitu, A. M., M. Petersson, C. L. O'Donnell, K. Williams, S. Jindal, R. Kiessling, and R. M. Welsh. 1998. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187: 685-691.
7. Suzue, K., and R. A. Young. 1996. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 156: 873-879.
8. Chen, C. H., T. L. Wang, C. F. Hung, Y. Yang, R. A. Young, D. M. Pardoll, and T. C. Wu. 2000. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60: 1035-1042.
9. Cho, B. K., D. Palliser, E. Guillen, J. Wisniewski, R. A. Young, J. Chen, and H. N. Eisen. 2000. A proposed mechanism for the induction of cytotoxic T lym-phocyte production by heat shock fusion proteins. Immunity 12: 263-272.
10. Moroi, Y., M. Mayhew, J. Trcka, M. H. Hoe, Y. Takechi, F. U. Hartl, J. E. Rothman, and A. N. Houghton. 2000. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc. Natl. Acad. Sci. USA 97: 3485-3490.
11. Castelli, C., A. M. Ciupitu, F. Rini, L. Rivoltini, A. Mazzocchi, R. Kiessling, and G. Parmiani. 2001. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61: 222-227.
12. + T cells. Nat. Immunol. 6: 593-599.
13. Huang, C., H. Yu, Q. Wang, W. Ma, D. Xia, P. Yi, L. Zhang, and X. Cao. 2004. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene. Cancer Sci. 95: 160-167.
14. Srivastava, P. K., A. B. DeLeo, and L. J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Nail. Acad. Sci. USA 83: 3407-3411.
15. + T cells in vivo. Proc. Natl. Acad. Sci. USA 91:. 3077-3081.
16. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117-120.
17. 2 in transgenic adenocarcinoma of mouse prostate cells. Cancer Res. 60: 4714-4718.
18. Nicchitta, C. V. 1998. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr. Opin. Immunol. 10: 103-109.
19. Janetzki, S., D. Palla, V. Rosenhauer, H. Lochs, J. J. Lewis, and P. K. Srivastava. 2000. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int. J. Cancer 88: 232-238.
20. Heike, M., A. Weinmann, K. Bethke, and P. R. Galle. 1999. Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines. Biochem. Pharmacol. 58: 1381-1387.
21. Przepiorka, D., and P. K. Srivastava. 1998. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol. Med. Today 4: 478-484.
22. Belli, F., A. Testeri, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, et al. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20: 4169-4180.
23. Mazzaferro, V., J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchiano, S. Andreola, et al. 2003. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9: 3235-3245.
24. Parmiani, G., A. Testori, M. Maio, C. Castelli, L. Rivoltini, L. Pilla, F. Belli, V. Mazzaferro, J. Coppa, R. Patuzzo, et al. 2004. Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res. 10: 8142-8146.
25. Rowse, G. J., R. M. Tempero, M. L. VanLith, M. A. Hollingsworth, and S. J. Gendler. 1998. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58: 315-321.
26. Siddiqui, J., M. Abe, D. Hayes, E. Shani, E. Yunis, and D. Kufe. 1988. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc. Natl. Acad. Sci. USA 85: 2320-2323.
27. Akagi, J., J. W. Hodge, J. P. McLaughlin, L. Gritz, G. Mazzara, D. Kufe, J. Schlom, and J. A. Kantor. 1997. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J. Immunother. 20: 38-47.
28. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
29. Gong, J., D. Chen, M. Kashiwaba, and D. Kufe. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3: 558-561.
30. Tanaka, Y., S. Koido, M. Ghana, C. Liu, and J. Gong. 2005. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J. Immunol. 174: 1274-1280.
31. Koido, S., Y. Tanaka, D. Chen, D. Kufe, and J. Gong. 2002. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 168: 2111-2117.
32. Stevenson, M. A., and S. K. Calderwood. 1990. Members of the 70-kilodalton heat shock protein family contain a highly conserved calmodulin-binding domain. Mol. Cell. Biol. 10: 1234-1238.
33. + T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 101: 316-324.
34. Kantor, J., K. Irvine, S. Abrams, H. Kaufman, J. DiPietro, and J. Schlom. 1992. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 84: 1084-1091.
35. Apostolopoulos, V., G. Chelvanayagam, P. X. Xing, and I. F. McKenzie. 1998. Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules. J. Immunol. 161: 767-775.
36. Greenlee, R. T., T. Murray, S. Bolden, and P. A. Wingo. 2000. Cancer statistics, 2000. CA Cancer J. Clin. 50: 7-33.
37. Peat, N., S. J. Gendler, N. Lalani, T. Duhig, and J. Taylor- Papadimitriou. 1992. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res. 52: 1954-1960.
38. Peng, P., A. Menoret, and P. K. Srivastava. 1997. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J. Immunol. Methods 204: 13-21.
39. Asea, A., E. Kabingu, M. A. Stevenson, and S. K. Calderwood. 2000. HSP70 peptide-bearing preparations act as chaperokines. Cell Stress Chaperones 5: 425-431.
40. Calderwood, S. K., J. R. Theriault, and J. Gong. 2005. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur. J. Immunol. 35: 2518-2527.
41. Liu, B., J. Dai, H. Zheng, D. Stoilova, S. Sun, and Z. Li. 2003. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc. Natl. Acad. Sci. USA 100: 15824-15829.
42. Mayer, M. P., and B. Bukau. 2005. Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci. 62: 670-684.
43. Roe, S. M., C. Prodromou, R. O'Brien, J. E. Ladbury, P. W. Piper, and L. H. Pearl. 1999. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42: 260-266.
44. Calderwood, S. K., J. R. Theriault, and J. Gong. 2005. How is the immune response affected by hyperthermia and heat shock proteins? Int. J. Hyperthermia 21: 713-716.
45. Delneste, Y., G. Magistrelli, J. Gauchat, J. Haeuw, J. Aubry, K. Nakamura, N. Kawakami-Honda, L. Goetsch, T. Sawamura, J. Bonnefoy, and P. Jeannin. 2002. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17: 353-362.
46. Jeannin, P., B. Bottazzi, M. Sironi, A. Doni, M. Rusnati, M. Presta, V. Maina, G. Magistrelli, J. F. Haeuw, G. Hoeffel, et al. 2005. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 22: 551-560.
47. Bukau, B., and A. L. Horwich. 1998. The Hsp70 and Hsp60 chaperone machines. Cell 92: 351-366.
48. Tang, D., M. A. Khaleque, E. L. Jones, J. R. Theriault, C. Li, W. H. Wong, M. A. Stevenson, and S. K. Calderwood. 2005. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 10: 46-58.
49. Fourie, A. M., P. A. Peterson, and Y. Yang. 2001. Characterization and regulation of the major histocompatibility complex-encoded proteins Hsp70-Hom and Hsp70-1/2. Cell Stress Chaperones 6: 282-295.
50. Ren, J., A. Bharti, D. Raina, W. Chen, R. Ahmad, and D. Kufe. 2006. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 25: 20-31.
51. Koido, S., M. Ohana, C. Liu, N. Nikrui, J. Durfee, A. Lerner, and J. Gong. 2004. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin. Immunol. 113: 261-269.
52. + T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 23: 413-419.
53. Toes, R. E., F. Ossendorp, R. Offringa, and C. J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189: 753-756.
54. Manjili, M. H., R. Henderson, X. Y. Wang, X. Chen, Y. Li, E. Repasky, L. Kazim, and J. R. Subjeck. 2002. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res. 62: 1737-1742.
55. Ueda, G., Y. Tamura, I. Hirai, K. Kamiguchi, S. Ichimiya, T. Torigoe, H. Hiratsuka, H. Sunakawa, and N. Sato. 2004. Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity. Cancer Sci. 95: 248-253.